Karyopharm Therapeutics Inc. (KPTI)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Karyopharm Therapeutics Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 10, 2026 | 0.0292 | 0.0299 | 0.0170 | 0.0174 | 146,821,550 |
| Nov 9, 2026 | 0.0440 | 0.0442 | 0.0350 | 0.0400 | 23,722,491 |
| Nov 6, 2026 | 0.0476 | 0.0558 | 0.0401 | 0.0549 | 104,537,598 |
| Nov 5, 2026 | 0.0539 | 0.0643 | 0.0501 | 0.0601 | 18,847,981 |
| Nov 4, 2026 | 0.0810 | 0.1274 | 0.0729 | 0.0729 | 40,915,199 |
| Nov 3, 2026 | 0.1100 | 0.1100 | 0.0820 | 0.0883 | 16,868,113 |
| Nov 2, 2026 | 0.1530 | 0.1600 | 0.0946 | 0.1120 | 47,445,500 |
| Oct 30, 2026 | 0.9020 | 0.9020 | 0.5842 | 0.6620 | 3,523,426 |
| Oct 29, 2026 | 0.8097 | 0.9869 | 0.7807 | 0.8798 | 6,845,525 |
| Oct 28, 2026 | 0.4560 | 0.9091 | 0.4560 | 0.8321 | 55,288,020 |
| Oct 27, 2026 | 0.4592 | 0.4829 | 0.4304 | 0.4800 | 996,614 |
| Oct 26, 2026 | 0.5084 | 0.5166 | 0.4224 | 0.4821 | 1,365,207 |
| Oct 23, 2026 | 0.5366 | 0.5550 | 0.4400 | 0.5175 | 1,963,966 |
| Oct 22, 2026 | 0.4370 | 0.5526 | 0.4222 | 0.5461 | 7,488,473 |
| Oct 21, 2026 | 0.3630 | 0.4360 | 0.3630 | 0.4244 | 1,616,516 |
| Oct 20, 2026 | 0.3400 | 0.3892 | 0.3400 | 0.3586 | 766,733 |
| Oct 19, 2026 | 0.4000 | 0.4000 | 0.3311 | 0.3460 | 1,258,369 |
| Oct 16, 2026 | 0.3509 | 0.4000 | 0.3300 | 0.3901 | 2,708,532 |
| Oct 15, 2026 | 0.3100 | 0.3522 | 0.3100 | 0.3508 | 1,399,094 |
| Oct 14, 2026 | 0.4274 | 0.4274 | 0.3150 | 0.3150 | 2,075,539 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Chief Accounting Officer | Sale | 4.8K | $1.6K | Oct 16, 2026 | |
| Chief Accounting Officer | Sale | 378 | $449.82 | Oct 1, 2026 | |
| Chief Accounting Officer | Sale | 19 | $38.38 | Sep 1, 2026 | |
| EVP, Chief Development Officer | Sale | 189 | $1.3K | Jul 28, 2026 | |
| Director | Grant/Award | 15.5K | -- | May 21, 2026 | |
| Director | Grant/Award | 15.5K | -- | May 21, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.0M | 8.8% | 13F |
BlackRock, Inc. | 1.5M | 6.7% | 13F |
ACORN CAPITAL ADVISORS, LLC | 1.2M | 5.4% | 13F |
Catalio Capital Management, LP | 976.2K | 4.3% | 13F |
UBS Group AG | 963.9K | 4.2% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 940.8K | 4.1% | 13F |
AQR CAPITAL MANAGEMENT LLC | 931.7K | 4.1% | 13F |
Avidity Partners Management LP | 884.9K | 3.9% | 13F |
ACADIAN ASSET MANAGEMENT LLC | 617.9K | 2.7% | 13F |
STRS OHIO | 542.5K | 2.4% | 13F |
Insiders
- Abate KristinChief Accounting Officer
- Poulton StuartEVP, Chief Development Officer
- Schor ChenDirector
- Oliger Christy J.Director
- BOHLIN GAREN GDirector
- Greene Barry EDirector
- PAKIANATHAN DEEPIKADirector
- Su ZhenDirector
- Paulson Richard A.President and CEO
- Mano MichaelEVP, CLO&Secretary
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors.
In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. On November 2, 2026, Karyopharm Therapeutics Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
based on 22.68M shares outstanding
30d Avg
28.25M
60d Avg
13.77M
90d Avg
9.28M
Signal8's dilution snapshot of KPTI as of Jun 30, 2026 records an effective S-3 shelf registration (effective May 14, 2026), an at-the-market sales agreement dated Feb 17, 2023, 7 outstanding warrant series and a PIPE closed Mar 26, 2026, from SEC filings. 1 insider reported 3 open-market sales of KPTI stock on Form 4 in the 90 days to Nov 17, 2026. Karyopharm Therapeutics Inc. (OTC: KPTI) is in the Healthcare sector (Medical - Pharmaceuticals).